Leerink Partnrs Comments on United Therapeutics Co.’s Q1 2024 Earnings (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR) – Stock analysts at Leerink Partnrs raised their Q1 2024 earnings per share estimates for United Therapeutics in a report released on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will earn $5.93 per share for the quarter, up from their previous estimate of $5.90. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $23.46 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q2 2024 earnings at $6.32 EPS and Q3 2024 earnings at $7.04 EPS.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business’s revenue was up 25.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.67 earnings per share.

A number of other brokerages also recently commented on UTHR. HC Wainwright reiterated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $213.00 to $215.00 in a report on Monday, February 12th. SVB Leerink assumed coverage on shares of United Therapeutics in a report on Monday, February 5th. They set an “outperform” rating and a $330.00 price target for the company. Wells Fargo & Company increased their target price on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $292.67.

United Therapeutics Stock Performance

UTHR opened at $236.93 on Thursday. The company has a market capitalization of $11.15 billion, a price-to-earnings ratio of 11.94 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. United Therapeutics has a 1-year low of $204.44 and a 1-year high of $261.54. The business has a 50 day moving average price of $231.20 and a two-hundred day moving average price of $228.44.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Rise Advisors LLC acquired a new position in shares of United Therapeutics in the 1st quarter valued at $32,000. Atlas Capital Advisors LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at $51,000. Northwestern Mutual Wealth Management Co. boosted its stake in United Therapeutics by 49.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 65 shares during the period. GAMMA Investing LLC acquired a new position in United Therapeutics in the 4th quarter worth $43,000. Finally, Neo Ivy Capital Management acquired a new position in United Therapeutics in the 2nd quarter worth $48,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $232.05, for a total transaction of $835,380.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,166.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $248.33, for a total value of $3,724,950.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $32,282.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $232.05, for a total transaction of $835,380.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $30,166.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 126,190 shares of company stock valued at $29,672,157. Company insiders own 12.50% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.